Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review

被引:19
作者
Riccioni, Graziano [1 ]
机构
[1] San Camillo Lellis Hosp, Cardiol Unit, Foggia, Italy
关键词
Atherosclerosis; intima-media thickness; atorvastatin; fluvastatin; lovastatin; pravastatin; simvastatin; rosuvastatin; ezetimibe; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; HIGH-RISK; LOWERING TREATMENT; STROKE PREVENTION; CLINICAL-PRACTICE; CELL BIOLOGY; ATHEROSCLEROSIS;
D O I
10.2174/092986709788186183
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Carotid artery intima-media thickness measured by ultrasound has been shown to be correlated with the presence of cardiovascular disease and is now accepted and used as a surrogate marker for atherosclerotic disease, an important organ damage of hypercholesterolemia. In particular, statins reduce ischemic heart disease, improve endothelial function, reduce pro-inflammatory cytokines, reduce left ventricular hypertrophy and adverse remodeling, and slow/arrest atherosclerotic process. This last effect represents one of the most important targets of lipid-lowering drugs, in particular, carotid intima-media thickness, and an early-onset of atherosclerotic process. The acute anti-inflammatory effects of statins should further be explored as a potential mediator of change in intima-media thickness. Larger randomized controlled trials with selected patients and more detailed measurements of carotid intima-media thickness are needed to determine the clinical practice implications of these findings in participants who have asymptomatic evidence of atherosclerosis. The aim of this review is to explore the effectiveness of several used statins on carotid intima-media thickness regression.
引用
收藏
页码:1799 / 1805
页数:7
相关论文
共 110 条
[11]  
Barth Jacques D., 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P129, DOI 10.2174/1568006043336339
[12]   3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes [J].
Blum, A ;
Simsolo, C ;
Hasin, Y .
ATHEROSCLEROSIS, 2004, 175 (01) :1-5
[13]   Nicotinic acid: an old drug with a promising future [J].
Bodor, E. T. ;
Offermanns, S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S68-S75
[14]   Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis [J].
Bose, Dirk ;
von Birgelen, Clemens ;
Erbel, Raimund .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) :925-932
[15]   Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk [J].
Brown, B. Greg ;
Zhao, Xue-Qiao .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8A) :58B-62B
[16]   Atherogenic lipoprotein particles in atherosclerosis [J].
Carmena, R ;
Duriez, P ;
Fruchart, JC .
CIRCULATION, 2004, 109 (23) :2-7
[17]   Fluvastatin: efficacy and safety in reducing cardiac events [J].
Chan, MY ;
Lee, CH .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (11) :1883-1895
[18]   Differential associations of statin and fibrate treatment with carotid arterial remodeling [J].
Chironi, G ;
Simon, A ;
Gariepy, R ;
Balice, M ;
Del-Pino, M ;
Levenson, J .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (11) :1476-1481
[19]   Carotid Intima-Media Thickness Measurements: Techniques and Clinical Relevance [J].
Coll, Blai ;
Feinstein, Steven B. .
CURRENT ATHEROSCLEROSIS REPORTS, 2008, 10 (05) :444-450
[20]   Fluvastatin - Clinical and safety profile [J].
Corsini, A ;
Jacobson, TA ;
Ballantyne, CM .
DRUGS, 2004, 64 (12) :1305-1323